Assy, N., Hochberg, Z., Amit, T., Shen-Orr, Z., Enat, R., and Baruch, Y.
(1997). Growth hormone-stimulated insulin-like growth factor (IGF) I
and IGF-binding protein-3 in liver cirrhosis. J. Hepatol. 27 , 796-802.
Beste, L.A., Green, P.K., Berry, K., Kogut, M.J., Allison, S.K., and
Ioannou, G.N. (2017). Effectiveness of hepatitis C antiviral treatment in
a USA cohort of veteran patients with hepatocellular carcinoma. J.
Hepatol. 67 , 32-39.
Børsheim, E., Bui, Q.U., Tissier, S., Kobayashi, H., Ferrando, A.A., and
Wolfe, R.R. (2008). Effect of amino acid supplementation on muscle mass,
strength and physical function in elderly. Clin. Nutr. 27, 189-195.
Brass, E.P. (2000). Supplemental carnitine and exercise. Am. J. Clin.
Nutr. 72 , 618s-623s.
Cacoub, P., Desbois, A.C., Isnard-Bagnis, C., Rocatello, D., and Ferri, C.
(2016). Hepatitis C virus infection and chronic kidney disease: Time for
reappraisal. J. Hepatol. 65 , s82-s94.
Ceglia, L., da Silva Morais, M., Park, L.K., Morris, E., Harris, S.S.,
Bischoff-Ferrari, H.A., Fielding, R.A., and Dawson-Hughes, B. (2010).
Multi-step immunofluorescent analysis of vitamin D receptor loci and
myosin heavy chain isoforms in human skeletal muscle. J. Mol. Histol.
41 , 137-142.
Cheng, Y., Dharancy, S., Malapel, M., and Desreumaux, P. (2005).
Hepatitis C virus infection down-regulates the expression of peroxisome
proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA
transferase 1A. World J. Gastroenterol. 11, 7591-7596.
Chiu, S.M., Tsai, M.C., Lin, C.Y., Chen, C.H., Lu, S.N., Hung, C.H., Sheen,
100
I.S., Chien, R.N., Lin, C.L., Hu, T.H., et al. (2020). Serial changes of renal
function after directly acting antivirals treatment for chronic hepatitis
C: A 1-year follow-up study after treatment. PLoS One 15, e0231102.
Cruz-Jentoft, A.J., Baeyens, J.P., Bauer, J.M., Boirie, Y., Cederholm, T.,
Landi, F., Martin, F.C., Michel, J.P., Rolland, Y., Schneider, S.M., et al.
(2010). Sarcopenia: European consensus on definition and diagnosis:
Report of the European Working Group on Sarcopenia in Older People.
Age Ageing 39, 412-423.
Czaja, A.J., Carpenter, H.A., Santrach, P.J., and Moore, S.B. (1998).
Host- and disease-specific factors affecting steatosis in chronic hepatitis
C. J. Hepatol. 29 , 198-206.
Dasarathy, S. (2012). Consilience in sarcopenia of cirrhosis. J Cachexia
Sarcopenia Muscle 3 , 225-237.
Donaghy, A.J., Delhanty, P.J., Ho, K.K., Williams, R., and Baxter, R.C.
(2002). Regulation of the growth hormone receptor/binding protein,
insulin-like growth factor ternary complex system in human cirrhosis. J.
Hepatol. 36 , 751-758.
Fabrizi, F., Plaisier, E., Saadoun, D., Martin, P., Messa, P., and Cacoub,
P. (2013). Hepatitis C virus infection, mixed cryoglobulinemia, and
kidney disease. Am. J. Kidney Dis. 61, 623-637.
Fioravante, M., Alegre, S.M., Marin, D.M., Lorena, S.L., Pereira, T.S.,
and Soares, E.C. (2012). Weight loss and resting energy expenditure in
patients with chronic hepatitis C before and during standard treatment.
Nutrition 28 , 630-634.
Flanagan, J.L., Simmons, P.A., Vehige, J., Willcox, M.D., and Garrett, Q.
(2010). Role of carnitine in disease. Nutr. Metab. (Lond.) 7 , 30.
Fouad, Y., Lazarus, J.V., Negro, F., Peck-Radosavljevic, M., Sarin, S.K.,
101
Ferenci, P., Esmat, G., Ghazinian, H., Nakajima, A., Silva, M., et al.
(2021). MAFLD considerations as a part of the global hepatitis C
elimination effort: an international perspective. Aliment. Pharmacol.
Ther. 53, 1080-1089.
Francoz, C., and Sola, E. (2019). Assessment of renal function in
cirrhosis: Sarcopenia, gender and ethnicity matter. J. Hepatol. 70 , 828830.
Gnoni, A., Longo, S., Gnoni, G.V., and Giudetti, A.M. (2020). Carnitine in
Human Muscle Bioenergetics: Can Carnitine Supplementation Improve
Physical Exercise? Molecules 25.
Hanai, T., Shiraki, M., Ohnishi, S., Miyazaki, T., Ideta, T., Kochi, T., Imai,
K., Suetsugu, A., Takai, K., Moriwaki, H., and Shimizu, M. (2016). Rapid
skeletal muscle wasting predicts worse survival in patients with liver
cirrhosis. Hepatol. Res. 46 , 743-751.
Hevonoja, T., Pentikäinen, M.O., Hyvönen, M.T., Kovanen, P.T., and Ala Korpela, M. (2000). Structure of low density lipoprotein (LDL) particles:
basis for understanding molecular changes in modified LDL. Biochim.
Biophys. Acta 1488 , 189-210.
Hoogeveen, R.C., Gaubatz, J.W., Sun, W., Dodge, R.C., Crosby, J.R., Jiang,
J., Couper, D., Virani, S.S., Kathiresan, S., Boerwinkle, E., and
Ballantyne, C.M. (2014). Small dense low-density lipoprotein-cholesterol
concentrations
predict
risk
for
coronary
heart
disease:
the
Atherosclerosis Risk In Communities (ARIC) study. Arterioscler. Thromb.
Vasc. Biol. 34 , 1069-1077.
Ichikawa, T., Miyaaki, H., Miuma, S., Motoyoshi, Y., Narita, S., Toda, S.,
Takahashi, Y., Honda, T., Yajima, H., Uehara, R., et al. (2019). Carotid
Intima-media Thickness and Small Dense Low-density Lipoprotein
Cholesterol Increase after One Year of Treatment with Direct-acting
Antivirals in Patients with Hepatitis C Virus Infection. Intern. Med. 58 ,
102
1209-1215.
Iritani, S., Imai, K., Takai, K., Hanai, T., Ideta, T., Miyazaki, T., Suetsugu,
A., Shiraki, M., Shimizu, M., and Moriwaki, H. (2015). Skeletal muscle
depletion is an independent prognostic factor for hepatocellular
carcinoma. J. Gastroenterol. 50 , 323-332.
Ito, T., Ishigami, M., Zou, B., Tanaka, T., Takahashi, H., Kurosaki, M.,
Maeda, M., Thin, K.N., Tanaka, K., Takahashi, Y., et al. (2021). The
epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with
individual and forecasting analysis, 1995-2040. Hepatol. Int. 15 , 366-379.
Izumi, N., Hayashi, N., Kumada, H., Okanoue, T., Tsubouchi, H.,
Yatsuhashi, H., Kato, M., Ki, R., Komada, Y., Seto, C., and Goto, S. (2014).
Once-daily simeprevir with peginterferon and ribavirin for treatmentexperienced
HCV
genotype
1-infected
patients
in
Japan:
the
CONCERTO-2 and CONCERTO-3 studies. J. Gastroenterol. 49 , 941-953.
Ji, D., Chen, G.F., Niu, X.X., Zhang, M., Wang, C., Shao, Q., Wu, V., Wang,
Y., Cheng, G., Hurwitz, S.J., et al. (2021). Non-alcoholic fatty liver
disease is a risk factor for occurrence of hepatocellular carcinoma after
sustained virologic response in chronic hepatitis C patients: A
prospective four-years follow-up study. Metabol Open 10 , 100090.
Karlas, T., Petroff, D., Sasso, M., Fan, J.G., Mi, Y.Q., de Lédinghen, V.,
Kumar, M., Lupsor-Platon, M., Han, K.H., Cardoso, A.C., et al. (2017).
Individual
patient
data
meta-analysis
of
controlled
attenuation
parameter (CAP) technology for assessing steatosis. J. Hepatol. 66, 10221030.
Katsanos, C.S., Kobayashi, H., Sheffield-Moore, M., Aarsland, A., and
Wolfe, R.R. (2006). A high proportion of leucine is required for optimal
stimulation of the rate of muscle protein synthesis by essential amino
acids in the elderly. Am. J. Physiol. Endocrinol. Metab. 291 , E381-387.
103
Katsiki, N., Mikhailidis, D.P., and Mantzoros, C.S. (2016). Non-alcoholic
fatty liver disease and dyslipidemia: An update. Metabolism 65, 11091123.
Kawagishi, N., Suda, G., Kimura, M., Maehara, O., Shimazaki, T.,
Yamada, R., Kitagataya, T., Shigesawa, T., Suzuki, K., Nakamura, A., et
al. (2020). High serum angiopoietin-2 level predicts non-regression of
liver stiffness measurement-based liver fibrosis stage after direct-acting
antiviral therapy for hepatitis C. Hepatol. Res. 50, 671-681.
Kawagishi, N., Suda, G., Nakamura, A., Kimura, M., Maehara, O.,
Suzuki, K., Nakamura, A., Ohara, M., Izumi, T., Umemura, M., et al.
(2018). Liver steatosis and dyslipidemia after HCV eradication by direct
acting antiviral agents are synergistic risks of atherosclerosis. PLoS One
13 , e0209615.
Kobayashi, M., Suzuki, F., Fujiyama, S., Kawamura, Y., Sezaki, H.,
Hosaka, T., Akuta, N., Suzuki, Y., Saitoh, S., Arase, Y., et al. (2017).
Sustained virologic response by direct antiviral agents reduces the
incidence of hepatocellular carcinoma in patients with HCV infection. J.
Med. Virol. 89, 476-483.
Koizumi, T., Nikaido, H., Hayakawa, J., Nonomura, A., and Yoneda, T.
(1988). Infantile disease with microvesicular fatty infiltration of viscera
spontaneously occurring in the C3H-H-2(0) strain of mouse with
similarities to Reye's syndrome. Lab. Anim. 22 , 83-87.
Korenaga, M., Wang, T., Li, Y., Showalter, L.A., Chan, T., Sun, J., and
Weinman,
S.A.
(2005).
Hepatitis
virus
core
protein
inhibits
mitochondrial electron transport and increases reactive oxygen species
(ROS) production. J. Biol. Chem. 280 , 37481-37488.
Krishnan, P., Schnell, G., Tripathi, R., Beyer, J., Reisch, T., Dekhtyar, T.,
Irvin, M., Xie, W., Fu, B., Burroughs, M., et al. (2018). Integrated
Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis
104
C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in
Japan. Antimicrob. Agents Chemother. 62 .
Lavanchy, D. (2011). Evolving epidemiology of hepatitis C virus. Clin.
Microbiol. Infect. 17 , 107-115. 10.1111/j.1469-0691.
Lee, J.J., Lin, M.Y., Chang, J.S., Hung, C.C., Chang, J.M., Chen, H.C.,
Yu, M.L., and Hwang, S.J. (2014). Hepatitis C virus infection increases
risk of developing end-stage renal disease using competing risk analysis.
PLoS One 9 , e100790.
Leslie, J., Geh, D., Elsharkawy, A.M., Mann, D.A., and Vacca, M. (2022).
Metabolic dysfunction and cancer in HCV: Shared pathways and mutual
interactions. J. Hepatol. 77, 219-236.
Lok, A.S., and McMahon, B.J. (2007). Chronic hepatitis B. Hepatology 45,
507-539.
Machado, M.V., Oliveira, A.G., and Cortez-Pinto, H. (2010). Hepatic
steatosis
in
patients
coinfected
with
human
immunodeficiency
virus/hepatitis C virus: a meta-analysis of the risk factors. Hepatology
52 , 71-78. 10.1002/hep.23619.
Magoulas, P.L., and El-Hattab, A.W. (2012). Systemic primary carnitine
deficiency: an overview of clinical manifestations, diagnosis, and
management. Orphanet J. Rare Dis. 7 , 68.
Martin, P., DiMartini, A., Feng, S., Brown, R., Jr., and Fallon, M. (2014).
Evaluation for liver transplantation in adults: 2013 practice guideline by
the American Association for the Study of Liver Diseases and the
American Society of Transplantation. Hepatology 59, 1144-1165.
Masuda, T., Shirabe, K., Ikegami, T., Harimoto, N., Yoshizumi, T.,
Soejima, Y., Uchiyama, H., Ikeda, T., Baba, H., and Maehara, Y. (2014).
Sarcopenia is a prognostic factor in living donor liver transplantation.
Liver Transpl. 20, 401-407.
105
McPherron, A.C., Lawler, A.M., and Lee, S.J. (1997). Regulation of
skeletal muscle mass in mice by a new TGF-beta superfamily member.
Nature 387 , 83-90.
Mettke, F., Schlevogt, B., Deterding, K., Wranke, A., Smith, A., Port, K.,
Manns, M.P., Vogel, A., Cornberg, M., and Wedemeyer, H. (2018).
Interferon-free therapy of chronic hepatitis C with direct-acting
antivirals does not change the short-term risk for de novo hepatocellular
carcinoma in patients with liver cirrhosis. Aliment. Pharmacol. Ther. 47 ,
516-525.
Misiani, R., Bellavita, P., Fenili, D., Vicari, O., Marchesi, D., Sironi, P.L.,
Zilio, P., Vernocchi, A., Massazza, M., Vendramin, G., and et al. (1994).
Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis
C virus. N. Engl. J. Med. 330 , 751-756.
Mitwalli, A.H., Al-Wakeel, J.S., Alam, A., Tarif, N., Abu-Aisha, H.,
Rashed, M., and Al Nahed, N. (2005). L-carnitine supplementation in
hemodialysis patients. Saudi J. Kidney Dis. Transpl. 16 , 17-22.
Miyanari, Y., Atsuzawa, K., Usuda, N., Watashi, K., Hishiki, T., Zayas,
M., Bartenschlager, R., Wakita, T., Hijikata, M., and Shimotohno, K.
(2007). The lipid droplet is an important organelle for hepatitis C virus
production. Nat. Cell Biol. 9, 1089-1097.
Moriwaki, H., Miwa, Y., Tajika, M., Kato, M., Fukushima, H., and Shiraki,
M. (2004). Branched-chain amino acids as a protein- and energy-source
in liver cirrhosis. Biochem. Biophys. Res. Commun. 313, 405-409.
Nagata, H., Nakagawa, M., Asahina, Y., Sato, A., Asano, Y., Tsunoda, T.,
Miyoshi, M., Kaneko, S., Otani, S., Kawai-Kitahata, F., et al. (2017).
Effect of interferon-based and -free therapy on early occurrence and
recurrence of hepatocellular carcinoma in chronic hepatitis C. J. Hepatol.
67 , 933-939.
106
Nakanishi, H., Kurosaki, M., Tsuchiya, K., Nakakuki, N., Takada, H.,
Matsuda, S., Gondo, K., Asano, Y., Hattori, N., Tamaki, N., et al. (2015).
L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis. Cli n.
Gastroenterol. Hepatol. 13 , 1540-1543.
Nishikawa, H., Shiraki, M., Hiramatsu, A., Moriya, K., Hino, K., and
Nishiguchi, S. (2016). Japan Society of Hepatology guidelines for
sarcopenia in liver disease (1st edition): Recommendation from the
working group for creation of sarcopenia assessment criteria. Hepatol.
Res. 46 , 951-963.
Noureddin, M., Wong, M.M., Todo, T., Lu, S.C., Sanyal, A.J., and Mena,
E.A. (2018). Fatty liver in hepatitis C patients post-sustained virological
response with direct-acting antivirals. World J. Gastroenterol. 24 , 12691277.
Ohara, M., Ogawa, K., Suda, G., Kimura, M., Maehara, O., Shimazaki,
T., Suzuki, K., Nakamura, A., Umemura, M., Izumi, T., et al. (2018). L Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients Wit h
Liver Cirrhosis. Hepatol Commun 2, 906-918.
Ohara, M., Suda, G., Kimura, M., Maehara, O., Shimazaki, T., Shigesawa,
T., Suzuki, K., Nakamura, A., Kawagishi, N., Nakai, M., et al. (2020a).
Analysis of the optimal psoas muscle mass index cut-off values, as
measured by computed tomography, for the diagnosis of loss of skeletal
muscle mass in Japanese people. Hepatol. Res. 50, 715-725.
Ohara, M., Suda, G., Kimura, M., Maehara, O., Shimazaki, T., Shigesawa,
T., Suzuki, K., Nakamura, A., Kawagishi, N., Nakai, M., et al. (2020b).
Computed tomography, not bioelectrical impedance analysis, is the
proper method for evaluating changes in skeletal muscle mass in liver
disease. JCSM Rapid Communications 3 , 103-114.
Perlemuter, G., Sabile, A., Letteron, P., Vona, G., Topilco, A., Chrétien, Y.,
107
Koike, K., Pessayre, D., Chapman, J., Barba, G., and Bréchot, C. (2002).
Hepatitis C virus core protein inhibits microsomal triglyceride transfer
protein activity and very low density lipoprotein secretion: a model of
viral-related steatosis. FASEB J. 16, 185-194.
Poynard, T., Ratziu, V., McHutchison, J., Manns, M., Goodman, Z.,
Zeuzem, S., Younossi, Z., and Albrecht, J. (2003). Effect of treatment with
peginterferon or interferon alfa-2b and ribavirin on steatosis in patients
infected with hepatitis C. Hepatology 38 , 75-85.
Price, J.C., Ma, Y., Scherzer, R., Korn, N., Tillinghast, K., Peters, M.G.,
Noworolski, S.M., and Tien, P.C. (2017). Human immunodeficiency virusinfected and uninfected adults with non-genotype 3 hepatitis C virus
have less hepatic steatosis than adults with neither infection. Hepatology
65 , 853-863.
Rawlings, N.D., and Barrett, A.J. (1990). Evolution of proteins of the
cystatin superfamily. J. Mol. Evol. 30 , 60-71.
Reig, M., Mariño, Z., Perelló, C., Iñarrairaegui, M., Ribeiro, A., Lens, S.,
Díaz, A., Vilana, R., Darnell, A., Varela, M., et al. (2016). Unexpected
high rate of early tumor recurrence in patients with HCV-related HCC
undergoing interferon-free therapy. J. Hepatol. 65 , 719-726.
Reuter, S.E., and Evans, A.M. (2012). Carnitine and acylcarnitines:
pharmacokinetic,
pharmacological
and
clinical
aspects.
Clin.
Pharmacokinet. 51 , 553-572.
Ridker, P.M., Danielson, E., Fonseca, F.A., Genest, J., Gotto, A.M., Jr. ,
Kastelein, J.J., Koenig, W., Libby, P., Lorenzatti, A.J., MacFadyen, J.G.,
et al. (2008). Rosuvastatin to prevent vascular events in men and women
with elevated C-reactive protein. N. Engl. J. Med. 359 , 2195-2207.
Roguljic, H., Nincevic, V., Bojanic, K., Kuna, L., Smolic, R., Vcev, A.,
Primorac, D., Vceva, A., Wu, G.Y., and Smolic, M. (2021). Impact of DAA
108
Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An
Update. Front. Pharmacol. 12 , 678546.
Rubbia-Brandt, L., Quadri, R., Abid, K., Giostra, E., Malé, P.J., Mentha,
G., Spahr, L., Zarski, J.P., Borisch, B., Hadengue, A., and Negro, F. (2000).
Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype
3. J. Hepatol. 33, 106-115.
Rudman, D., Sewell, C.W., and Ansley, J.D. (1977). Deficiency of carnitine
in cachectic cirrhotic patients. J. Clin. Invest. 60, 716-723.
Sakamoto, N., and Watanabe, M. (2009). New therapeutic approaches to
hepatitis C virus. J. Gastroenterol. 44, 643-649.
Schmidt-Arras, D., and Rose-John, S. (2016). IL-6 pathway in the liver:
From physiopathology to therapy. J. Hepatol. 64, 1403-1415.
Silvério, R., Laviano, A., Rossi Fanelli, F., and Seelaender, M. (2011). l carnitine and cancer cachexia: Clinical and experimental aspects. J
Cachexia Sarcopenia Muscle 2, 37-44.
Suda, G., Hasebe, C., Abe, M., Kurosaki, M., Itakura, J., Izumi, N.,
Uchida, Y., Mochida, S., Haga, H., Ueno, Y., et al. (2019a). Safety and
efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis
patients with genotype 2 hepatitis C virus infection. J. Gastroenterol. 54 ,
641-649.
Suda, G., Nakai, M., Sho, T., Kimura, M., Shimazaki, T., Maehara, O.,
Shigesawa, T., Suzuki, K., Nakamura, A., Ohara, M., et al. (2019b). The
Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1
or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A
and Protease Inhibitor Treatment. Intern. Med. 58 , 943-947.
Suda, G., Ogawa, K., Morikawa, K., and Sakamoto, N. (2018). Treatment
of hepatitis C in special populations. J. Gastroenterol. 53, 591-605.
109
Suda, G., and Sakamoto, N. (2021). Recent advances in the treatment of
hepatitis C virus infection for special populations and remaining
problems. J. Gastroenterol. Hepatol. 36, 1152-1158.
Suda, G., Sakamoto, N., Itsui, Y., Nakagawa, M., Tasaka-Fujita, M.,
Funaoka, Y., Watanabe, T., Nitta, S., Kiyohashi, K., Azuma, S., et al.
(2010).
IL-6-mediated
intersubgenotypic
variation
of
interferon
sensitivity in hepatitis C virus genotype 2a/2b chimeric clones. Virology
407 , 80-90.
Sugimoto, R., Iwasa, M., Hara, N., Tamai, Y., Yoshikawa, K., Ogura, S.,
Tanaka, H., Eguchi, A., Yamamoto, N., Kobayashi, Y., et al. (2018).
Changes in liver function and body composition by direct-acting antiviral
therapy for hepatitis C virus infection. Hepatol. Res. 48 , 337-344.
Sun, H.Y., Cheng, P.N., Tseng, C.Y., Tsai, W.J., Chiu, Y.C., and Young,
K.C. (2018). Favouring modulation of circulating lipoproteins and lipid
loading capacity by direct antiviral agents grazoprevir/elbasvir or
ledipasvir/sofosbuvir treatment against chronic HCV infection. Gut 67,
1342-1350.
Syed, G.H., Tang, H., Khan, M., Hassanein, T., Liu, J., and Siddiqui, A.
(2014). Hepatitis C virus stimulates low-density lipoprotein receptor
expression to facilitate viral propagation. J. Virol. 88 , 2519-2529.
Takehara, T., Sakamoto, N., Nishiguchi, S., Ikeda, F., Tatsumi, T., Ueno,
Y., Yatsuhashi, H., Takikawa, Y., Kanda, T., Sakamoto, M., et al. (2019).
Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in
HCV-infected Japanese patients with decompensated cirrhosis: an openlabel phase 3 trial. J. Gastroenterol. 54 , 87-95.
Teramoto, T., Sasaki, J., Ishibashi, S., Birou, S., Daida, H., Dohi, S.,
Egusa, G., Hiro, T., Hirobe, K., Iida, M., et al. (2014). Other types of
primary hyperlipoproteinemia(hyperlipidemia). Executive summary of
110
the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and
prevention of atherosclerotic cardiovascular diseases in Japan--2012
version. J Atheroscler Thromb 21, 82-85.
Tsai, M.C., Lin, C.Y., Hung, C.H., Lu, S.N., Tung, S.Y., Chien, R.N., Lin,
C.L., Wang, J.H., Chien-Hung, C., Chang, K.C., et al. (2019). Evolution
of renal function under direct-acting antivirals treatment for chronic
hepatitis C: A real-world experience. J. Viral Hepat. 26 , 1404-1412.
Tsuge, M., Hiramatsu, A., Shinohara, F., Nakano, N., Nakamura, Y.,
Hatooka, M., Morio, K., Morio, R., Kan, H., Fujino, H., et al. (2016).
Improvement of renal dysfunction in a patient with hepatitis C virus related liver cirrhosis by daclatasvir and asunaprevir combination
therapy: A case report. Hepatol. Res. 46 , 944-948.
Tsukuda, Y., Suda, G., Tsunematsu, S., Ito, J., Sato, F., Terashita, K.,
Nakai, M., Sho, T., Maehara, O., Shimazaki, T., et al. (2017). Anti adipogenic and antiviral effects of l-carnitine on hepatitis C virus
infection. J. Med. Virol. 89, 857-866.
Vallet-Pichard, A., Mallet, V., Nalpas, B., Verkarre, V., Nalpas, A.,
Dhalluin-Venier, V., Fontaine, H., and Pol, S. (2007). FIB-4: an
inexpensive and accurate marker of fibrosis in HCV infection.
comparison with liver biopsy and fibrotest. Hepatology 46, 32-36.
Wiesner, R., Edwards, E., Freeman, R., Harper, A., Kim, R., Kamath, P.,
Kremers, W., Lake, J., Howard, T., Merion, R.M., et al. (2003). Model for
end-stage liver disease (MELD) and allocation of donor livers.
Gastroenterology 124, 91-96.
Yoo, J.J., Kim, S.G., Kim, Y.S., Lee, B., Lee, M.H., Jeong, S.W., Jang, J.Y.,
Lee, S.H., Kim, H.S., Kim, Y.D., and Cheon, G.J. (2019). Estimation of
renal function in patients with liver cirrhosis: Impact of muscle mass and
sex. J. Hepatol. 70 , 847-854.
111
...
論文の公開元へ
